The rapid growth of GLP-1 therapeutics has driven increasing demand for efficient, scalable, and cost-effective peptide manufacturing technologies. Recombinant enzyme-based processing offers a powerful approach to improving peptide maturation efficiency, reducing manufacturing complexity, and supporting large-scale production.
Yeasen provides a comprehensive Semaglutide manufacturing solution featuring recombinant enterokinase, Kex2 protease, carboxypeptidase B, and semaglutide intermediate peptide — supporting efficient peptide drug production from process development to manufacturing scale-up.
Key Highlights
Ready-to-Use Semaglutide Intermediate
Accelerate Manufacturing with High-Purity Peptide Building Blocks
High-Precision Enterokinase
Enable Efficient Cleavage with Superior Specificity, RUO grade (Cat#20395ES) and GMP grade ready.
High‑Yield Complementary‑Specificity Tandem Cleavage
Recombinant Kex2 Protease + Carboxypeptidase B
GMP-Grade Enzyme Manufacturing Platform
Ensure Reliable Supply with Scalable Production Capacity
Highlighted Products & Performance
High Purity: Semaglutide Intermediate Peptide
Ready-to-use peptide building blocks with >98% purity, accelerating downstream semaglutide production.
Figure . P29-Arg34 GLP-1 (9–37) intermediate peptide with >98% purity, verified by HPLC analysis.
High-Precision: Recombinant Enterokinase(Single Enzyme Cleavage)
Enable efficient fusion tag removal with superior cleavage specificity.
Workflow: Fusion Protein → Enterokinase Cleavage → Semaglutide Intermediate Peptide
A. High Purity
Figure . SDS-PAGE analysis showing >95% purity(Cat#20395ES)
B. High Specificity
Figure . Cleavage efficiency comparison between Yeasen recombinant enterokinase (Cat#20395ES) and Supplier N* under identical reaction conditions. The recombinant enterokinase demonstrated superior cleavage performance with higher substrate conversion and reduced nonspecific cleavage.
C. Strong Stability
Figure . Stability evaluation of recombinant enterokinase GMP-grade (Cat#20396ES) under repeated freeze–thaw cycles and accelerated storage conditions. The enzyme maintained consistent activity and structural integrity, demonstrating robust stability suitable for manufacturing workflows.
High-Yield: Recombinant Kex2 Protease + Carboxypeptidase B(Tandem Enzyme Cleavage )
Enable high-yield precursor peptide maturation through complementary cleavage.
Workflow:
Fusion Protein → Kex2 Protease Cleavage → Intermediate Peptide → Carboxypeptidase B Polishing
High Yield and Purity
Figure . Tandem enzymatic processing of P29-Arg34 GLP-1 (9–37) using recombinant Kex2 protease and carboxypeptidase B. The two-step cleavage workflow achieved high substrate conversion with high product purity, supporting efficient precursor peptide maturation
Powered by Yeasen GMP-Grade Enzyme Manufacturing Platform
Reliable Enzyme Supply for Next-Generation GLP-1 Manufacturing
Driven by continuous innovation and process optimization, Yeasen continuously improves the quality, consistency, and production capacity of key enzymes for semaglutide manufacturing, including recombinant enterokinase, Kex2 protease, and carboxypeptidase B.
With flexible product grades and scalable manufacturing capabilities, Yeasen supports customers throughout different production stages, from process development to large-scale manufacturing.
Manufacturing Advantages
✓ Continuous optimization of enzyme quality and performance
✓ Multiple grades and specifications to meet diverse application needs
✓ Scalable production from R&D to commercial manufacturing
✓ Reliable supply of key enzymes for peptide production
GMP-Grade Enzyme Manufacturing Platform
Yeasen’s UCF.ME™ platform is an ISO-certified ultra-clean molecular enzyme manufacturing facility equipped with advanced fermentation, purification, analytical, and automated production systems.
With scalable manufacturing capabilities from 5 L to 1,500 L, UCF.ME™ provides reliable enzyme supply and manufacturing support for research, process development, and industrial production.
Accelerate Your Semaglutide Manufacturing Workflow
From high-performance recombinant enzymes to ready-to-use peptide intermediates, Yeasen provides reliable and scalable solutions to support next-generation GLP-1 peptide manufacturing.
Contact Yeasen to explore customized solutions for your peptide production workflow.
Frequently Asked Questions (FAQ)
1.Why choose recombinant enterokinase for semaglutide production?
Recombinant enterokinase provides highly specific cleavage by recognizing the Asp-Asp-Asp-Asp-Lys (DDDDK) sequence, enabling efficient removal of fusion tags or carrier sequences with minimal nonspecific cleavage.
Compared with conventional processing approaches, recombinant enterokinase offers:
- High cleavage specificity
- Consistent batch performance
- Reduced process complexity
- Scalability for industrial manufacturing
2.What is the difference between enterokinase and Kex2/CPB tandem processing?
Enterokinase and Kex2/CPB support different peptide processing strategies:
|
|
Recombinant Enterokinase |
Kex2 Protease + Carboxypeptidase B |
|
Recognition site |
DDDDK cleavage site |
Paired basic residues (e.g., KR, RR) |
|
Primary function |
Precise fusion tag removal |
Precursor peptide maturation |
|
Workflow complexity |
Single-enzyme, streamlined |
Dual-enzyme, complementary |
|
Best suited for |
Streamlined single-enzyme processing workflows, suitable for scale-up and industrial production. |
Complex peptide processing requiring terminal amino acid modification and high-yield Semaglutide intermediate production. |
The optimal enzyme combination depends on the specific production design and process requirements.
3.Can Yeasen support scale-up from R&D to commercial manufacturing?
Yes. Yeasen's UCF.ME™ platform provides scalable manufacturing capabilities from 5 L to 1,500 L fermentation volume. This allows customers to:
Validate enzyme performance at R&D scale
Optimize process parameters during pilot production
Scale up to commercial manufacturing volumes with consistent quality
Batch-to-batch consistency is maintained through standardized fermentation, purification, and analytical workflows.
4. How does Yeasen support large-scale production?
Yeasen's GMP-oriented manufacturing platform and production capabilities support stable supply and scalable manufacturing, helping customers transition from process development toward commercial production.
5. Can the solution be customized for different manufacturing processes?
Yes. Different enzymatic cleavage strategies can be selected according to the customer's process requirements, including single-enzyme Enterokinase cleavage or tandem Kex2 protease + Carboxypeptidase B processing.
6. What are the key advantages of Yeasen's solution?
The solution combines high-quality intermediates, efficient recombinant enzymes, simplified processing, high-yield enzymatic cleavage, and scalable manufacturing support—helping make GLP-1 peptide production more efficient and easier to scale.
Related Products
|
Product Category |
Product Name |
Cat. No. |
|
Semaglutide Intermediate Peptide |
20381ES |
|
|
Recombinant Enterokinase & Supporting Product |
20395ES |
|
|
20396ES |
||
|
20391ES |
||
|
20394ES |
||
|
20393ES |
||
|
Recombinant Kex2 Protease & Supporting Product |
20418ES |
|
|
20385ES |
||
|
20384ES |
||
|
20383ES |
||
|
20417ES |
||
|
20374ES |
||
|
20373ES |
||
|
In Vitro Activity Detection |
11411ES |
|
|
11404ES |
||
|
11412ES |
||
|
40211ES |